Biogen's (BIIB) stock price has increased rapidly in the past few years, leaving investors wondering if the stock price has finally exceeded its fair value range (a range between which we think the stock is fairly valued). To answer this question, we perform a rigorous discounted cash-flow methodology and assign an appropriate margin of safety to our point fair value estimate (key components of our Valuentum Buying Index). If Biogen's stock price falls outside this range, only then do we consider the stock to be undervalued or overvalued. Let's see if Biogen is still reasonably valued despite its meteoric share price rise.
Our Report on Biogen
• Biogen is a global biotech firm that focuses on therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The firm continues to advance its pipeline, and global AVONEX performance remains strong.
• Biogen earns a ValueCreation™ rating of EXCELLENT, the highest possible mark on our scale. The firm has been generating economic value for shareholders for the past few years, a track record we view very positively. We expect the firm's return on invested capital (excluding goodwill) to expand to 56.2% from 38.4% during the next two years.
• Biogen has an excellent combination of strong free cash flow generation and low financial leverage. We expect the firm's free cash flow margin to average about 34.2% in coming years. Total debt-to-EBITDA was 0.5 last year, while debt-to-book capitalization stood at 14.2%.
• The firm's share price performance has trailed that of the market during the past quarter. However, it is trading within our fair value estimate range, so we don't view such activity as alarming.
Economic Profit Analysis
The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital (ROIC) with its weighted average cost of capital (OTC:WACC). The gap or difference between ROIC and WACC is called the firm's economic profit spread. Biogen's 3-year historical return on invested capital (without goodwill) is 36.6%, which is above the estimate of its cost of capital of 10.6%. As such, we assign the firm a ValueCreation™ rating of EXCELLENT. In the chart below, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate.
Cash Flow Analysis
Firms that generate a free cash flow margin (free cash flow divided by total revenue) above 5% are usually considered cash cows. Biogen's free cash flow margin has averaged about 28.7% during the past 3 years. As such, we think the firm's cash flow generation is relatively STRONG. The free cash flow measure shown above is derived by taking cash flow from operations less capital expenditures and differs from enterprise free cash flow (FCFF), which we use in deriving our fair value estimate for the company. For more information on the differences between these two measures, please visit our website at Valuentum.com. At Biogen, cash flow from operations increased about 61% from levels registered two years ago, while capital expenditures expanded about 52% over the same time period.
Our discounted cash flow model indicates that Biogen's shares are worth between $88.00 - $163.00 each. The margin of safety around our fair value estimate is driven by the firm's MEDIUM ValueRisk™ rating, which is derived from the historical volatility of key valuation drivers. So to answer the question posed by this article, Biogen has not yet breached the high end of our fair value range, so we're not ready to say it has moved too far too fast. In fact, we think the stock remains fairly valued. The estimated fair value of $125 per share represents a price-to earnings (P/E) ratio of about 24.8 times last year's earnings and an implied EV/EBITDA multiple of about 14 times last year's EBITDA. Our model reflects a compound annual revenue growth rate of 7.6% during the next five years, a pace that is higher than the firm's 3-year historical compound annual growth rate of 7.2%. Our model reflects a 5-year projected average operating margin of 41.2%, which is above Biogen's trailing 3-year average. Beyond year 5, we assume free cash flow will grow at an annual rate of 3.7% for the next 15 years and 3% in perpetuity. For Biogen, we use a 10.6% weighted average cost of capital to discount future free cash flows.
Margin of Safety Analysis
Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows. Although we estimate the firm's fair value at about $125 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future was known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values. Our ValueRisk™ rating sets the margin of safety or the fair value range we assign to each stock. In the graph below, we show this probable range of fair values for Biogen. We think the firm is attractive below $88 per share (the green line), but quite expensive above $163 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.
Future Path of Fair Value
We estimate Biogen's fair value at this point in time to be about $125 per share. As time passes, however, companies generate cash flow and pay out cash to shareholders in the form of dividends. The chart below compares the firm's current share price with the path of Biogen's expected equity value per share over the next three years, assuming our long-term projections prove accurate. The range between the resulting downside fair value and upside fair value in Year 3 represents our best estimate of the value of the firm's shares three years hence. This range of potential outcomes is also subject to change over time, should our views on the firm's future cash flow potential change. The expected fair value of $170 per share in Year 3 represents our existing fair value per share of $125 increased at an annual rate of the firm's cost of equity less its dividend yield. The upside and downside ranges are derived in the same way, but from the upper and lower bounds of our fair value estimate range.
Pro Forma Financial Statements